Mantle Cell Lymphoma-Pipeline Review, H2 2016

Mantle Cell Lymphoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8348IDB
  • |
  • Pages: 426
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mantle Cell Lymphoma-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Mantle Cell Lymphoma-Pipeline Review, H2 2016', provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma

The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Mantle Cell Lymphoma Overview 10

Therapeutics Development 11

Pipeline Products for Mantle Cell Lymphoma-Overview 11

Pipeline Products for Mantle Cell Lymphoma-Comparative Analysis 12

Mantle Cell Lymphoma-Therapeutics under Development by Companies 13

Mantle Cell Lymphoma-Therapeutics under Investigation by Universities/Institutes 17

Mantle Cell Lymphoma-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Mantle Cell Lymphoma-Products under Development by Companies 21

Mantle Cell Lymphoma-Products under Investigation by Universities/Institutes 26

Mantle Cell Lymphoma-Companies Involved in Therapeutics Development 27

AB Science SA 27

AbbVie Inc 28

Acetylon Pharmaceuticals, Inc. 29

Actinium Pharmaceuticals, Inc. 30

Affimed GmbH 31

Amgen Inc. 32

Asana BioSciences, LLC 33

Astellas Pharma Inc. 34

Astex Pharmaceuticals, Inc. 35

Bayer AG 36

BeiGene, Ltd. 37

Bristol-Myers Squibb Company 38

Celgene Corporation 39

Cellular Biomedicine Group, Inc. 40

Eisai Co., Ltd. 41

Eli Lilly and Company 42

EpiZyme, Inc. 43

Gilead Sciences, Inc. 44

GlaxoSmithKline Plc 45

Hutchison MediPharma Limited 46

ImmunoGen, Inc. 47

Immunomedics, Inc. 48

Incyte Corporation 49

Inflection Biosciences Limited 50

Johnson & Johnson 51

Juno Therapeutics Inc. 52

Karyopharm Therapeutics, Inc. 53

Kite Pharma, Inc. 54

LFB S.A. 55

MacroGenics, Inc. 56

MedImmune, LLC 57

Merck & Co., Inc. 58

Merck KGaA 59

Millennium Pharmaceuticals Inc 60

MorphoSys AG 61

Nordic Nanovector ASA 62

Novartis AG 63

Onconova Therapeutics, Inc. 64

Oncternal Therapeutics, Inc. 65

Patrys Limited 66

Pharmacyclics, Inc. 67

Portola Pharmaceuticals, Inc. 68

Seattle Genetics, Inc. 69

Selvita S.A. 70

Stemline Therapeutics, Inc. 71

Takeda Pharmaceutical Company Limited 72

TG Therapeutics, Inc. 73

Vivolux AB 74

Mantle Cell Lymphoma-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 82

Assessment by Route of Administration 87

Assessment by Molecule Type 89

Drug Profiles 91

(INCB-039110 + INCB-040093)-Drug Profile 91

13197-Drug Profile 92

AB-8779-Drug Profile 94

abexinostat hydrochloride-Drug Profile 95

acalabrutinib-Drug Profile 98

ACY-241-Drug Profile 101

ACY-775-Drug Profile 103

AFM-11-Drug Profile 104

alisertib-Drug Profile 105

AMG-319-Drug Profile 110

ASN-002-Drug Profile 112

AT-7519-Drug Profile 113

avicin d-Drug Profile 116

BC-8Y90-Drug Profile 117

bendamustine hydrochloride-Drug Profile 118

Betalutin-Drug Profile 121

BGB-3111-Drug Profile 125

BLyS-gel-Drug Profile 127

BMS-986016-Drug Profile 128

buparlisib hydrochloride-Drug Profile 130

carfilzomib-Drug Profile 135

CBM-C19.1-Drug Profile 147

CBM-C20.1-Drug Profile 148

Cellular Immunotherapy for Oncology-Drug Profile 150

Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 151

cerdulatinib-Drug Profile 152

copanlisib hydrochloride-Drug Profile 156

daratumumab-Drug Profile 160

denintuzumab mafodotin-Drug Profile 171

durvalumab-Drug Profile 174

E-7449-Drug Profile 184

entospletinib-Drug Profile 185

epratuzumab-Drug Profile 187

EPZ-015666-Drug Profile 194

HMPL-523-Drug Profile 195

IBL-301-Drug Profile 197

ibrutinib-Drug Profile 199

IGN-002-Drug Profile 224

IMGN-529-Drug Profile 226

IMMU-114-Drug Profile 228

INA-01-Drug Profile 230

INCB-40093-Drug Profile 231

INCB-50465-Drug Profile 232

inebilizumab-Drug Profile 233

inebilizumab + MEDI-0680-Drug Profile 235

Iomab-B-Drug Profile 236

itacitinib adipate-Drug Profile 241

ixazomib citrate-Drug Profile 244

JCAR-014-Drug Profile 253

JCAR-015-Drug Profile 256

JCAR-017-Drug Profile 261

JNJ-64052781-Drug Profile 264

KTEC-19-Drug Profile 266

LAM-002A-Drug Profile 273

M-7583-Drug Profile 274

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections-Drug Profile 275

Monoclonal Antibodies to Target ROR1 and CD3 for Oncology-Drug Profile 276

MOR-208-Drug Profile 277

ON-123300-Drug Profile 282

ONC-201-Drug Profile 283

OSU-2S-Drug Profile 287

PATLM-1-Drug Profile 288

PCAR-019-Drug Profile 290

pembrolizumab-Drug Profile 291

ramucirumab-Drug Profile 322

ribociclib succinate-Drug Profile 332

S-055746-Drug Profile 337

sapanisertib-Drug Profile 338

SEL-120-Drug Profile 341

SEL-12034-Drug Profile 343

SEL-24B489-Drug Profile 345

selinexor-Drug Profile 346

SGN-CD70A-Drug Profile 363

SL-101-Drug Profile 364

spebrutinib besylate-Drug Profile 365

TAK-659-Drug Profile 367

TGR-1202-Drug Profile 368

tisagenlecleucel-T-Drug Profile 375

tretinoin-Drug Profile 380

ublituximab-Drug Profile 381

UC-961-Drug Profile 388

venetoclax-Drug Profile 390

VLX-1570-Drug Profile 399

vorinostat-Drug Profile 401

Mantle Cell Lymphoma-Dormant Projects 405

Mantle Cell Lymphoma-Discontinued Products 408

Mantle Cell Lymphoma-Product Development Milestones 409

Featured News & Press Releases 409

Appendix 418

Methodology 418

Coverage 418

Secondary Research 418

Primary Research 418

Expert Panel Validation 418

Contact Us 418

Disclaimer 419

List of Tables

Number of Products under Development for Mantle Cell Lymphoma, H2 2016 18

Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Development by Companies, H2 2016 (Contd..4) 32

Products under Investigation by Universities/Institutes, H2 2016 33

Mantle Cell Lymphoma-Pipeline by AB Science SA, H2 2016 34

Mantle Cell Lymphoma-Pipeline by AbbVie Inc, H2 2016 35

Mantle Cell Lymphoma-Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 36

Mantle Cell Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 37

Mantle Cell Lymphoma-Pipeline by Affimed GmbH , H2 2016 38

Mantle Cell Lymphoma-Pipeline by Amgen Inc., H2 2016 39

Mantle Cell Lymphoma-Pipeline by Asana BioSciences, LLC, H2 2016 40

Mantle Cell Lymphoma-Pipeline by Astellas Pharma Inc., H2 2016 41

Mantle Cell Lymphoma-Pipeline by Astex Pharmaceuticals, Inc., H2 2016 42

Mantle Cell Lymphoma-Pipeline by Bayer AG, H2 2016 43

Mantle Cell Lymphoma-Pipeline by BeiGene, Ltd., H2 2016 44

Mantle Cell Lymphoma-Pipeline by Bristol-Myers Squibb Company, H2 2016 45

Mantle Cell Lymphoma-Pipeline by Celgene Corporation, H2 2016 46

Mantle Cell Lymphoma-Pipeline by Cellular Biomedicine Group, Inc., H2 2016 47

Mantle Cell Lymphoma-Pipeline by Eisai Co., Ltd., H2 2016 48

Mantle Cell Lymphoma-Pipeline by Eli Lilly and Company, H2 2016 49

Mantle Cell Lymphoma-Pipeline by EpiZyme, Inc., H2 2016 50

Mantle Cell Lymphoma-Pipeline by Gilead Sciences, Inc., H2 2016 51

Mantle Cell Lymphoma-Pipeline by GlaxoSmithKline Plc, H2 2016 52

Mantle Cell Lymphoma-Pipeline by Hutchison MediPharma Limited, H2 2016 53

Mantle Cell Lymphoma-Pipeline by ImmunoGen, Inc., H2 2016 54

Mantle Cell Lymphoma-Pipeline by Immunomedics, Inc., H2 2016 55

Mantle Cell Lymphoma-Pipeline by Incyte Corporation, H2 2016 56

Mantle Cell Lymphoma-Pipeline by Inflection Biosciences Limited, H2 2016 57

Mantle Cell Lymphoma-Pipeline by Johnson & Johnson, H2 2016 58

Mantle Cell Lymphoma-Pipeline by Juno Therapeutics Inc., H2 2016 59

Mantle Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H2 2016 60

Mantle Cell Lymphoma-Pipeline by Kite Pharma, Inc., H2 2016 61

Mantle Cell Lymphoma-Pipeline by LFB S.A., H2 2016 62

Mantle Cell Lymphoma-Pipeline by MacroGenics, Inc., H2 2016 63

Mantle Cell Lymphoma-Pipeline by MedImmune, LLC, H2 2016 64

Mantle Cell Lymphoma-Pipeline by Merck & Co., Inc., H2 2016 65

Mantle Cell Lymphoma-Pipeline by Merck KGaA, H2 2016 66

Mantle Cell Lymphoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 67

Mantle Cell Lymphoma-Pipeline by MorphoSys AG, H2 2016 68

Mantle Cell Lymphoma-Pipeline by Nordic Nanovector ASA, H2 2016 69

Mantle Cell Lymphoma-Pipeline by Novartis AG, H2 2016 70

Mantle Cell Lymphoma-Pipeline by Onconova Therapeutics, Inc., H2 2016 71

Mantle Cell Lymphoma-Pipeline by Oncternal Therapeutics, Inc., H2 2016 72

Mantle Cell Lymphoma-Pipeline by Patrys Limited, H2 2016 73

Mantle Cell Lymphoma-Pipeline by Pharmacyclics, Inc., H2 2016 74

Mantle Cell Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H2 2016 75

Mantle Cell Lymphoma-Pipeline by Seattle Genetics, Inc., H2 2016 76

Mantle Cell Lymphoma-Pipeline by Selvita S.A., H2 2016 77

Mantle Cell Lymphoma-Pipeline by Stemline Therapeutics, Inc., H2 2016 78

Mantle Cell Lymphoma-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 79

Mantle Cell Lymphoma-Pipeline by TG Therapeutics, Inc., H2 2016 80

Mantle Cell Lymphoma-Pipeline by Vivolux AB, H2 2016 81

Assessment by Monotherapy Products, H2 2016 82

Assessment by Combination Products, H2 2016 83

Number of Products by Stage and Target, H2 2016 85

Number of Products by Stage and Mechanism of Action, H2 2016 90

Number of Products by Stage and Route of Administration, H2 2016 95

Number of Products by Stage and Molecule Type, H2 2016 97

Mantle Cell Lymphoma-Dormant Projects, H2 2016 412

Mantle Cell Lymphoma-Dormant Projects (Contd..1), H2 2016 413

Mantle Cell Lymphoma-Dormant Projects (Contd..2), H2 2016 414

Mantle Cell Lymphoma-Discontinued Products, H2 2016 415

List of Figures

Number of Products under Development for Mantle Cell Lymphoma, H2 2016 18

Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 82

Number of Products by Top 10 Targets, H2 2016 84

Number of Products by Stage and Top 10 Targets, H2 2016 84

Number of Products by Top 10 Mechanism of Actions, H2 2016 89

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 89

Number of Products by Routes of Administration, H2 2016 94

Number of Products by Stage and Routes of Administration, H2 2016 94

Number of Products by Molecule Types, H2 2016 96

Number of Products by Stage and Molecule Types, H2 2016 96

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AB Science SA

AbbVie Inc

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Affimed GmbH

Amgen Inc.

Asana BioSciences, LLC

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Bayer AG

BeiGene, Ltd.

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EpiZyme, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Inflection Biosciences Limited

Johnson & Johnson

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

LFB S.A.

MacroGenics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

MorphoSys AG

Nordic Nanovector ASA

Novartis AG

Onconova Therapeutics, Inc.

Oncternal Therapeutics, Inc.

Patrys Limited

Pharmacyclics, Inc.

Portola Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Selvita S.A.

Stemline Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

TG Therapeutics, Inc.

Vivolux AB

Mantle Cell Lymphoma Therapeutic Products under Development, Key Players in Mantle Cell Lymphoma Therapeutics, Mantle Cell Lymphoma Pipeline Overview, Mantle Cell Lymphoma Pipeline, Mantle Cell Lymphoma Pipeline Assessment

select a license
Single User License
USD 2000 INR 142760
Site License
USD 4000 INR 285520
Corporate User License
USD 6000 INR 428280

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com